Bone health and fracture risk during ADT for prostate cancer
Loading player...
Dr Omondi Ogude highlights bone health and fracture risk for prostate cancer patients who are on androgen deprivation therapy.
This episode is proudly brought to you by Aspen Pharmacare in the interest of education, awareness, and support. As we observe Men’s Health Month this June, we’re turning the spotlight on the unique challenges and triumphs men face on their cancer journey — encouraging a culture of openness and proactive health.
Dr Omondi Ogude is a medical oncologist serving as a director of the Sandton Oncology Medical Group and practices at the Sandton Oncology Centre. He specialises in breast, gastrointestinal, and gynaecological malignancies and is actively involved in research. He serves as a principal investigator and sub-investigator on multiple trials. He also chairs and sits on various multi-disciplinary forums in Johannesburg and advisory boards locally and internationally.
This episode is proudly brought to you by Aspen Pharmacare in the interest of education, awareness, and support. As we observe Men’s Health Month this June, we’re turning the spotlight on the unique challenges and triumphs men face on their cancer journey — encouraging a culture of openness and proactive health.
Dr Omondi Ogude is a medical oncologist serving as a director of the Sandton Oncology Medical Group and practices at the Sandton Oncology Centre. He specialises in breast, gastrointestinal, and gynaecological malignancies and is actively involved in research. He serves as a principal investigator and sub-investigator on multiple trials. He also chairs and sits on various multi-disciplinary forums in Johannesburg and advisory boards locally and internationally.
